Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xarelto in symptomatic peripheral artery disease after revascularization
NCT02504216Phase 3Completed
- Sponsor
- Bayer
- Start
- Aug 2015
- Primary completion
- Nov 2019
- Countries
- 34
01
Overview
Phase 3, randomised, double-blind trial in peripheral artery disease (PAD) comparing Rivaroxaban Arm with Placebo Arm (2 arms). Primary endpoints: Composite of Myocardial Infarction, Ischemic Stroke, Cardiovascular Death, Acute Limb Ischemia, and Major Amputation at 1110 days and TIMI Major Bleeding. Started Aug 2015; status: completed.
02
Drugs
rivaroxaban
03
Conditions
peripheral artery disease (PAD)
Beyond the preview
Go deeper on NCT02504216.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02504216.